Investment Rating - The report does not explicitly state an investment rating for the eczema ointment industry Core Insights - The Chinese eczema ointment market is characterized by a growing demand for innovative solutions that balance efficacy and safety, driven by a trend of patient consumerization and the prevalence of unsafe products containing illegal additives [3][5] - The report emphasizes that only products with the "National Drug Approval Number" can ensure safety and efficacy, highlighting the non-hormonal innovative drug, Zeli Mei® (Benvimod Ointment), as a representative of the future market direction [3][8] Summary by Sections Market Overview - Eczema is a chronic, recurrent, itchy, and inflammatory skin disease affecting 15% to 30% of dermatology patients [13][29] - Topical medications account for 67% of eczema treatments, with non-hormonal topical agents becoming increasingly important due to the potential adverse effects of long-term steroid use [13][30] - The market for eczema ointments is projected to grow from approximately 5.5 billion yuan in 2019 to 7.44 billion yuan by 2029, with a compound annual growth rate (CAGR) of 7.5% from 2025 to 2029 [43][45] Product Categories and Efficacy Analysis - The report identifies various types of topical agents and their effectiveness, noting that treatment strategies should be adjusted based on the stage of eczema: acute, subacute, and chronic [47][52] - Non-hormonal innovative drugs like Benvimod Ointment are highlighted for their clinical advantages in efficacy and safety compared to traditional treatments [30][33] Patient Behavior and Awareness - Patients prioritize ingredient safety and brand reputation when purchasing eczema medications, with a significant shift towards online and branded channels for drug acquisition [6][36] - The consumerization of healthcare is evident, with patients actively seeking information and making informed decisions about their treatments [40][41] Market Challenges and Regulatory Landscape - The report discusses the prevalence of misleading marketing and unsafe products in the eczema ointment market, emphasizing the need for strict regulatory compliance and consumer education [7][8] - The "National Drug Approval Number" is presented as a critical standard for ensuring the safety and efficacy of eczema treatments, with a trend towards increased regulatory scrutiny [8][43]